Pilomotor seizures marked by infraslow activity and acetazolamide responsiveness

Richard Wennberg1,2, Catherine Maurice1, Peter L. Carlen1 & Luis Garcia Dominguez1,2

1Krembil Brain Institute, Division of Neurology, University Health Network, University of Toronto, Toronto, Canada
2Mitchell Goldhar MEG Unit, Clinical Neurophysiology Laboratory, Toronto Western Hospital, University of Toronto, Toronto, Canada

Abstract

A patient with pilomotor seizures post anti-LGI1 limbic encephalitis, refractory to immunotherapy and anti-epileptic drugs, was investigated with electroencephalography and magnetoencephalography. Seizures occurred daily (14.9 ± 4.9/day), with catamenial exacerbation, inducible by hyperventilation. Anterior temporal ictal onsets were heralded (by ~15 sec) by high amplitude ipsilateral electromagnetic infraslow activity. The catamenial/ventilatory sensitivity and the infraslow activity (reflecting glial depolarization) suggested an ionic, CO2/pH-related glioneuronal mechanism. Furosemide decreased seizure frequency by ~33%. Acetazolamide led to immediate seizure freedom, but lost efficacy with daily treatment. A cycling acetazolamide regimen (2 days on, 4 days off) plus low-dose topiramate maintained >95% reduction (0.5 ± 0.9/day) in seizures.

Introduction

Patients with voltage-gated potassium channel complex limbic encephalitis attributable to leucine-rich glioma-inactivated 1 (LGI1) auto-antibodies – anti-LGI1 encephalitis (ALGI1E) – frequently present with pathognomonic lateralized motor spasms known as faciobrachial dystonic or tonic-dystonic seizures,1–3 characterized in electroencephalography (EEG) recordings by an electrodecremental pattern and a contralateral frontal lobe “DC shift”, or infraslow activity (ISA).1,4 Temporal lobe seizures also occur in ALGI1E patients,1,3,6 often subclinical and with atypical EEG features, including sensitivity to hyperventilation.1,4,5 In patients with clinical temporal lobe seizures a pilomotor semiology is common, which has been described to reflect mesial temporal, and possibly insular, ictal activity.3,6–9

We describe a patient post-ALGI1E with medically refractory pilomotor seizures sensitive to hyperventilation and menstruation. Seizures were heralded by conspicuous lateralized ISA, recorded with EEG and magnetoencephalography (MEG). MEG showed an ipsilateral magnetodcremental pattern during the ISA, beginning ~15 sec before the appearance of rhythmic ictal activity over the ipsilateral temporal lobe. Seizures were singularly responsive to a cycling regimen of acetazolamide drug therapy. The clinical, neurophysiologic, and pharmacologic features suggested a glioneuronal mechanism of seizure generation, and a specific, mechanistically guided treatment.

Subject and Methods

Case history

A 35-year-old woman was referred for video-EEG investigation of daily episodes of “chills,” associated with goosebumps, diaphoresis, and pallor. Episodes lasted ~15 sec, with no alteration of consciousness. Piloerection affected both arms, right > left. The patient tracked event occurrences (mean 14.9 ± 4.9/day) by smartphone screen capture of date and time. She noted a marked catamenial exacerbation. Episodes were refractory to carbamazepine, valproate, levetiracetam, and clobazam.

Eighteen months earlier, the patient began to experience memory difficulties and episodic diaphoresis, ultimately presenting to hospital with hyponatremia and a generalized tonic-clonic seizure. Brain MRI showed bilateral mesial temporal FLAIR hyperintensities and LGI1 antibodies were identified in serum. Other investigations were normal. There were no motor spasms. She was treated with intravenous immunoglobulin (IVIG) and...
methyldprednisolone followed by oral prednisone, plasmapheresis ~2 months after IVIG, and then rituximab. Prednisone was tapered to discontinuation after 7 months. IVIG was administered a few months later because of ongoing episodes. Repeat serum and CSF analyses were negative for LGI1 antibodies 8, 12, and 18 months after onset of symptoms. Repeated MRI scans showed stable diminution of the initial mesial temporal hyperintensities.

**EEG and MEG recordings**

Continuous 32-channel video-EEG was obtained using Natus/Xltek (Oakville, Canada) EMU40 amplifiers, sampling frequency 256 Hz, analog bandwidth 0.07–100 Hz, input impedance >100 mΩ. Simultaneous MEG/EEG was acquired using an Elekta Neuromag TRIUX system (Helsinki, Finland), sampling frequency 1000 Hz, analog bandwith 0.03-330 Hz, tSSS artifact suppression (500-sec time window). Offline analyses and digital filtering used Insight (Persyst, Prescott, USA) and Curry 6 (Compumedics, Abbotsford, Australia).

**Ictal MEG beamformer source reconstruction**

Ictal source reconstruction applied dynamic imaging of coherent sources (DICS) frequency domain beamforming, implemented in FieldTrip. Ictal events were epoched into n trials of 1-sec duration; n = seizure duration in seconds. Randomly selected interictal periods of the same duration were similarly epoched (n = 500). Spectral comparisons of ictal versus interictal sets were plotted as average power over all channels and topographic power over sensor space for each frequency. The frequency of largest difference between the two sets was chosen for DICS computation. Both sets were pooled together to obtain a common beamformer filter. This filter was then applied independently to each set of trials, the end result displayed as the relative difference in power between ictal and interictal periods.

**Results**

**EEG recordings**

Ninety-four seizures were recorded during 6 days of video-EEG monitoring. The patient activated the event marker with every seizure, including seizures arising from sleep, and each subjective event was associated with a right or left temporal seizure lasting 15–25 sec, appearing as rhythmic 2–5 Hz activity maximal at F8/F10 > T4/T10 on the right and F7/F9 > T3/T9 on the left. Right-sided seizures were ~3 times more common. The sensation of the seizures was perceived as identical by the patient, irrespective the EEG lateralization.

Hyperventilation performed seven times induced electroclinical seizures (four left, three right) during 6 of the 3-min over-breathing epochs. Hyperventilation into a paper bag (repeated 3 times) had no activating effect.

The peri-ictal EEG segments were subsequently reviewed without the digital high-pass filter, and the rhythmic onset of each seizure was found to be heralded 15–20 sec earlier by a slow baseline shift recorded first ipsilaterally and then contralaterally to the eventual temporal seizure (Fig. 1). Prior to right temporal seizures this ISA occurred as a slow positivity peaking over the right centrotemporoparietal region, followed by a slow positivity peaking over the left central region, whereas left temporal seizures were preceded by similar ISA appearing first over the left centrotemporoparietal region. Analyzed with slow sweep speed in average referential montage, seizures could be easily identified and lateralized solely by the ISA visible in the broadband EEG recording. The ISA pattern was specific to seizure occurrences and could be appreciated in the standard clinical 0.5–70 Hz band-pass range, even in bipolar montages, but was much more evident after removal of the digital high-pass filter. Clinical onset tended to occur just after ISA onset, ~15 sec before the rhythmic ictal EEG pattern (Fig. 1), the latter presumably representing propagation from a mesial temporal or, possibly, insular site of seizure onset.

Interictically, rare right anterior temporal epileptiform discharges occurred during sleep on 2 days.
MEG recording and ictal source reconstruction

Three seizures (two right, one left) occurred during the 90-min MEG/EEG study. The ISA was more evident in EEG than MEG, but MEG showed to advantage a widespread ipsilateral amplitude decrement of cortical activity beginning at the time of ISA onset (Fig. 2A and B).

Figure 2C shows the localization results of the ictal events. Only the later, propagated rhythmic ictal periods could be modeled; no focal, earlier source of ictal activity during the ISA/magnetodecremental periods was identified. The ISA itself was unlocalizable, suggesting that the equivalent current dipole model, implicit in the forward model leadfield matrix, may not be applicable to ISA and its presumed glial/glioneuronal generation.12

Responsiveness to drug therapy

Given sensitivity to menses, hyperventilation and the ISA findings, a trial of furosemide 20 mg daily was initiated, with the rationale that ionomic imbalances might underlie the putative glioneuronal/ISA seizure generating mechanism, and that inhibition of astrocytic Na+/K+/Cl co-transporters (and modulation of cell swelling/extracellular space volume) might be beneficial.13,14 A 52-day trial was associated with a significant, yet clinically suboptimal, decrease in seizure frequency to 10.1 ± 3.4/day (P < 0.0001, unpaired t-test, two-tailed; Fig. 3A).

Acetazolamide was then substituted for furosemide, with the rationale that its inhibitory effects on astrocytic carbonic anhydrase might more directly target a CO2/pH-sensitive mechanism.14,15 After commencement of acetazolamide 125 mg bid the patient experienced her first seizure-free day in more than 6 months. The seizure-free period lasted 44 hours, before daily seizures recurred, albeit at a lower frequency (7.1 ± 3.7/day). Switching to alternate day dosing or 2 days on/2 days off was insufficient to regain seizure-freedom. Ultimately, a cycling regimen (2 days on/4 days off) was identified that produced a significant reduction in seizures by 95% to 0.5 ± 0.9/day (P = 0.0000; Fig. 3B and C).

Discussion

The glycoprotein LGI1 forms part of a trans-synaptic bridge between presynaptic voltage-gated Kv1.1 potassium channels and postsynaptic AMPA receptors, but it is not known how LGI1 antibodies cause epilepsy, nor why so many features of extratemporal and temporal seizures in ALGI1E are distinct from other autoimmune or non-encephalitic epilepsies.6,7,9,16 Regarding neuronal hyperexcitability, LGI1 expressed at the axonal initial segment was recently demonstrated to regulate action potential firing by setting the density of axonal Kv1.1 channels that mediate dendrotoxin-sensitive D-type potassium currents.17 The generation of ISA is poorly understood, although given the slow time course glioneuronal mechanisms related to spreading depolarization/depression are important considerations and were hypothesized to underlie ISA preceding the motor spasms of ALGI1E.4 The electromagnetic ISA characterizing pilomotor seizures in this patient, combined with catamenial/ventilatory sensitivity and acetazolamide responsiveness, further suggests glioneuronal interactivity in epileptogenesis post-ALGI1E.

Increased extracellular potassium related to sustained neuronal activity can lead to glial depolarization and ISA; moreover, signaling across the astrocytic syncytium can coordinate gliotransmitter release and reciprocally affect neuronal activity.4,12,18,19 Separately, ISA induced by experimental CO2/pH manipulations has been interpreted to represent non-neuronal, non-glial potential differences across the endothelial blood–brain barrier.18

Although one cannot exclude an endothelial contribution, the ISA/magnetodecremental pattern presented here is consistent with glioneuronal generation, similar to that underlying ictal ISA/electrodecremental patterns.4,12 Whether abnormal glial or neuronal activity initiates the process is unclear: sensitivity to menses and hyperventilation suggests glial initiation, but only indirectly. The location and polarity of the sequential ISA peaks are difficult to understand: the non-dipolar topographies are consistent with non-neuronal sources, but the peak maxima are perplexing, perhaps attributable to bihemispheric spatial buffering of potassium throughout the astroglial syncytium,19 although such an hypothesis is untestable at this time.

Acetazolamide increases sodium excretion and induces metabolic acidosis, but its main anti-epileptic effects are due to carbonic anhydrase inhibition, increasing neuronal [CO2], and decreasing glial pH and [HCO3−], potentially modulating interglial gap junctional communication. Habituation with daily use is recognized,15 although the rapidity of habituation in this case was unexpected and awaits explanation.

The confluence of clinical, electromagnetic and pharmacologic features in this case is extraordinary. Our previous ALGI1E patients with hyperventilation-sensitive subclinical seizures5 did not show ictal ISA. However, another report of pilomotor seizures appears to show similar ISA before a left temporal seizure (see figure 3 in
Figure 2. (A) Simultaneous MEG and EEG recording of a right-sided pilomotor seizure. Selected right hemispheric MEG channels shown (10 magnetometer, 36 gradiometer) from total 306-channel acquisition. ISA evident in MEG, but much more prominent in EEG, the first (\(\wedge\)), second (\(\wedge\wedge\)) and third (\(\wedge\wedge\wedge\)) ISA peaks accentuated (compared to the EEG recordings in Fig. 1) because of the longer time constant (LFF 0.03 Hz). Coincident with ISA onset, a distinct amplitude suppression of faster cortical rhythms is apparent in the MEG recording, beginning to recover after \(\sim\)7.5 sec (around the time of the second ISA peak), regaining baseline amplitudes \(\sim\)15 sec after ISA onset, just before the appearance of rhythmic ictal activity over the right temporal lobe (horizontal bar). M = magnetometers. G1 = planar gradiometers. G2 = planar gradiometers (orthogonal to G1). HFF 30 Hz. (B) Time-frequency plot of broadband (0.03–330 Hz) MEG signal from right hemisphere sensors over the 15-min period surrounding the seizure shown in (A). ISA epoch from onset to return to baseline marked by vertical lines: plot shows decrease in power (blue) of right hemispheric activity during ISA. Topographic plots above show alpha frequency (\(\sim\)10 Hz) suppression maximal over centrotemporoparietal area and beta frequency (\(\sim\)20 Hz) suppression maximal more anteriorly, over frontotemporal area (whole head 204 gradiometer channel data). Rhythmic right temporal ictal pattern evident in time-frequency plot as increased power (red) in delta band (underlined). (C) Beamformer source reconstruction of the rhythmic ictal signal from two right temporal seizures (top) and a left temporal seizure (bottom) recorded with MEG shows ictal localization to the anterobasolateral temporal regions (gradiometer data, results thresholded at 99.5%; single-shell forward model based on subject’s brain MRI scan). Insets: topographic plots of MEG log spectral power differences between the rhythmic component of the ictal periods and interictal baseline periods at a central frequency 2 Hz (204 orthogonal gradiometer sensors). Beamformer analyses of the ISA component of the three ictal events did not return meaningful MEG source solutions. No interictal epileptiform discharges were recorded.
Figure 3. (A) Daily pilomotor seizure frequency over seven months in 2017 shows catamenial exacerbations, slight decrease during daily furosemide (20 mg) trial (first horizontal black bar), and 44-h period of transient seizure freedom (arrow) at start of one-month acetazolamide (125 mg BID) trial (second horizontal black bar). Other antiepileptic drugs (AEDs): levetiracetam 1500 mg BID June to October, decreased to 500 mg BID at commencement of furosemide; clobazam 10 mg daily August to October, discontinued at commencement of furosemide. Vertical black bars = first day of menstrual cycle. Horizontal grey bars = days of video-EEG and MEG recording (first), repeat 24-h video-EEG recording (second). (B) Daily seizure frequency over seven months in 2018 shows 46-h period of seizure freedom (arrow) after reintroduction of acetazolamide, two-day course, 125 mg BID, end of January. Over the next weeks two-day courses of acetazolamide 125 mg BID (single horizontal bars) were alternated with progressively shortened drug-free intervals to determine optimal cycling regimen: efficacy was lost or diminished at intervals less than 4 days. Three weeks later, acetazolamide reintroduced in a cycling 250 mg BID regimen, 2 days on (double horizontal bars), 4 days off, with repeated periods of seizure freedom lasting ~72 h. Acetazolamide dosage increased to 375 mg BID mid June, same 2 days on (triple horizontal bars), 4 days off regimen, with periods of seizure-freedom lasting 84–144 h. Other AEDs: levetiracetam 500 mg BID, decreased to 250 mg BID early June, discontinued mid-June (to relieve emotional adverse effects); phenytoin (started December 30, 2017) 500 mg daily; topiramate (long horizontal bar; gradually uptitrated to 50 mg BID July. (C) Continuation of seizure frequency graph in (B), same cycling acetazolamide 375 mg BID regimen, topiramate downtitrated to 25 mg BID (to relieve paresthesiae, blurred vision adverse effects). Vertical black bars = first day of menstrual cycle.
reference\textsuperscript{20}), implying the phenomena described here are likely not unique to our patient.

**Conflicts of Interest**

None of the authors have any potential conflict of interest.

**Author Contributions**

Conception and study design (RW, LGD); data acquisition and analysis (RW, CM, PLC, LGD); manuscript and figure preparation (RW, LGD). All authors critically reviewed the manuscript and approved the final draft.

**References**

1. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 2011;76:1355–1357.
2. Irani S, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:889–900.
3. Navarro V, Kas A, Apartis E, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 2016;139:1079–1093.
4. Wennberg R, Steriade C, Chen R, Andrade D. Frontal infraslow activity marks the motor spams of anti-LGI1 encephalitis. Clin Neurophysiol 2018;129:59–68.
5. Steriade C, Mirsattari SM, Murray BJ, Wennberg R. Subclinical temporal EEG seizure pattern in LGI1-antibody—mediated encephalitis. Epilepsia 2016;57:e155–e160.
6. Aurangzeb S, Symmonds M, Knight RK, et al. LGI1-antibody encephalitis is characterized by frequent, multifocal clinical and subclinical seizures. Seizure 2017;50:14–17.
7. Wieser S, Kelemen A, Barsi P, et al. Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord 2005;7:205–211.
8. Rocamora R, Becerra JL, Fossas P, et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 2014;23:670–673.
9. Binks SNM, Klein CJ, Waters P, et al. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018;89:526–534.
10. Gross J, Kujala J, Hamalainen L, et al. Dynamic imaging of coherent sources: studying neural interactions in the human brain. Proc Natl Acad Sci U S A 2001;98:694–699.
11. Oostenveld R, Fries P, Maris E, Schoffelen J-M. FieldTrip: open source software for advanced analysis of MEG, EEG and invasive electrophysiological data. Comp Intell Neurosci 2011;2011:156869. https://doi.org/10.1155/2011/156869.
12. Ikeda A, Taki W, Kunieda T, et al. Focal ictal direct current shifts in human epilepsy as studied by subdural and scalp recording. Brain 1999;122:827–838.
13. Hochman DW. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia 2012;53 (Suppl 1):18–25.
14. Woodbury DM, Engstrom FL, White HS, et al. Ionic and acid-base regulation of neurons and glia during seizures. Ann Neurol 1984;16(Suppl):S135–S144.
15. Ansell B, Clarke E. Acetazolamide in treatment of epilepsy. Br Med J 1956;1:650–654.
16. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 2017;97:839–887.
17. Seagar M, Russier M, Caillard O, et al. LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channels. Proc Natl Acad Sci USA 2017;114:7719–7724.
18. Vanhatalo S, Voipio J, Kaila K. Infraslow EEG activity. In: D. L. Schomer, F. H. Lopes da Silva, eds. Niedermeyer’s electroencephalography: basic principles, clinical applications, and related fields. 6th ed. pp. 741–747. Philadelphia: Lippincott Williams & Wilkins, 2011.
19. Crunelli V, Carmignoto G, Steinhäuser C. Novel astrocyte targets: new avenues for the therapeutic treatment of epilepsy. Neuroscientist 2015;21:62–83.
20. Masnou P, Gagnepain J-P, Fouad A, et al. Pilomotor seizures associated with sequential changes in magnetic resonance imaging. Epileptic Disord 2006;8:232–237.